Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Table 3_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

Three classic combustion stages of the flame. by Lei Bai (631944)

“…The main findings of this study are as follows: (1) As the temperature of the hot surface increases, the ignition delay time generally shows a decreasing trend, with 450°C being a critical turning point; (2) There is an overlap between ignition and non-ignition cases within a specific range, forming a possible ignition zone, and the <i>R</i>² values of the fitting equations for the upper and lower boundaries are both above 95%, indicating a good fit. (3) The fractal dimension can effectively quantify the geometric complexity of the flame’s outer contour, thereby characterizing the stability of the flame’s combustion. …”

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects:

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)